Physician profile
Scott D Helms
NPI 1033229638
$5,331.23
in general payments reported to CMS, 2019-2025
52 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $1,164 · 2023: $926 · 2024: $908 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.06 | 2021-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $313.61 | 2022-2025 | |
| Seagen INC. | $310.18 | 2021-2023 | Padcev, Adcetris |
| Eisai INC. | $280.78 | 2021-2025 | |
| Gilead Sciences, INC. | $229.70 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $220.31 | 2022-2025 | Keytruda, Welireg |
| Abbvie INC. | $213.23 | 2021-2025 | |
| Janssen Biotech, INC. | $209.06 | 2021-2025 | Rybrevant, Tecvayli, Darzalex |
| Blueprint Medicines Corporation | $192.40 | 2021-2025 | Ayvakit |
| Daiichi Sankyo INC. | $181.97 | 2021-2025 | Enhertu |
| Glaxosmithkline, LLC. | $176.54 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Karyopharm Therapeutics INC. | $170.87 | 2021-2023 | Xpovio |
| Genentech USA, INC. | $160.40 | 2022-2025 | Lunsumio, Polivy, Columvi |
| Genzyme Corporation | $159.98 | 2021-2025 | |
| Amgen INC. | $146.36 | 2021-2023 | Lumakras |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $144.19 | 2021-2023 | Opdivo |
| Celgene Corporation | $130.79 | 2022-2023 | Pomalyst, Opdualag |
| Beigene USA, INC. | $126.31 | 2023-2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $122.30 | 2021-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $120.56 | 2021-2025 | |
| Epizyme, INC. | $99.82 | 2021-2023 | Tazverik |
| Legend Biotech USA INC. | $98.81 | 2024-2025 | Carvykti |
| Pfizer INC. | $94.43 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.44 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $73.79 | 2021-2023 | Libtayo |
| Jazz Pharmaceuticals INC. | $63.03 | 2021-2022 | |
| Incyte Corporation | $61.04 | 2021-2023 | Jakafi, Pemazyre, Monjuvi |
| Beone Medicines USA, INC. | $54.76 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $50.33 | 2025 | Clonoseq |
| Astellas Pharma US INC | $50.33 | 2023-2024 | Padcev |
| Acrotech Biopharma INC. | $49.04 | 2022-2025 | Beleodaq |
| Recordati_rare_diseases_inc. | $30.43 | 2025 | Enjaymo |
| Alexion Pharmaceuticals, INC. | $30.03 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $28.84 | 2022-2023 | Xarelto |
| Iovance Biotherapeutics, INC. | $26.55 | 2025 | Amtagvi |
| Geron Corporation | $20.51 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $20.48 | 2023 | Cosela |
| Stemline Therapeutics INC. | $20.06 | 2023 | Orserdu |
| Syndax Pharmaceuticals, INC. | $19.98 | 2025 | |
| Sobi, INC | $19.41 | 2024 | |
| Mirati Therapeutics, INC. | $18.93 | 2023 | Krazati |
| Genmab U.S., INC. | $17.59 | 2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $17.32 | 2022 | |
| Adc Therapeutics America, INC. | $17.16 | 2022 | |
| Array Biopharma INC | $16.82 | 2025 | Braftovi, Mektovi, Tukysa |
| Novocure INC. | $15.71 | 2025 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $14.40 | 2022 | |
| Exelixis INC. | $13.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.66 | 2021 | |
| Puma Biotechnology, INC. | $12.79 | 2022 | |
| Cti Biopharma Corp. | $12.64 | 2022 | |
| Myovant Sciences INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.